Latest News
EQL licenses Memprex for Hungarian market through Pharmacenter
12 August 2026 - Swedish pharmaceutical company EQL Pharma AB (STO: EQL) announced on Wednesday that it has licensed its methenamine hippurate product Memprex for sale in Hungary through local pharmaceutical company Pharmacenter, which develops and c...
Definium Therapeutics reports positive Phase 3 results for DT120 in generalised anxiety disorder
12 August 2026 - Late-stage clinical biopharmaceutical company Definium Therapeutics Inc (Nasdaq:DFTX) on Wednesday reported positive topline results from its Phase 3 Voyage study evaluating DT120 (lysergide) Orally Disintegrating Tablet (ODT) 100 mi...
Astorg completes acquisition of Thermo Fisher Scientific's microbiology business
12 August 2026 - Private equity firm Astorg announced on Wednesday that it has completed its acquisition of the global microbiology business of life science and clinical research company Thermo Fisher Scientific Inc (NYSE:TMO), establishing an indepe...
Natera to support Phase 1 trial of Kupando's immunotherapy in advanced skin cancers
12 August 2026 - Cell-free DNA and precision medicine company Natera Inc (NASDAQ:NTRA) said on Wednesday that it will provide its Latitude tissue-free molecular residual disease (MRD) assay for a Phase 1 clinical trial sponsored by Kupando Therapeuti...
AlzeCure completes QuantumCell transaction with USD12m upfront payment
12 August 2026 - Swedish biotech company AlzeCure Pharma AB (FN STO:ALZCUR) announced on Wednesday that it has received the full USD12m upfront payment from Danish biotech company QuantumCell ApS under their licensing and collaboration agreement for ...